Adaptive Biotechnologies Corp
Company Stats
- Market Cap
- $4.6B
- as of Sep 30, 2026
- Shares Outstanding
- 159.6M
- Free Float
- 94.1%
Income Statement
- Revenue
- $277.0M
- Operating Income
- -$57.1M
- Net Income
- -$59.5M
- EBITDA
- -$41.0M
- Revenue Growth, 3Y
- 14.3%
- FCF Margin, 3Y Avg
- -57.0%
- FCF Margin, Worst Year
- -98.1%
Cash Flow
- Free Cash Flow
- -$48.9M
- FCF Yield
- -1.1%
- Owner FCF Yield
- -2.2%
Balance Sheet
- Cash & Equivalents
- $70.5M
Returns & Capital
- SBC, 3Y Avg
- $56.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $277.0M | -$48.9M | -17.7% |
| FY2024 | $179.0M | -$98.9M | -55.3% |
| FY2023 | $170.3M | -$167.0M | -98.1% |
| FY2022 | $185.3M | -$200.3M | -108.1% |
| FY2021 | $154.3M | -$254.5M | -164.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 30, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back
Bitmine Hits $10.7B Treasury; Booz Allen Expands Defense Tech